Study of Xeligekimab for non-radiographic axial spondyloarthritis
Treatments studied
Part of Bones, joints & muscles clinical trials.
This trial tests a new medication called Xeligekimab for people with a type of arthritis called non-radiographic axial spondyloarthritis, which causes inflammation in the spine and joints. The goal is to see if the drug can reduce symptoms like pain and stiffness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a diagnosis of non-radiographic axial spondyloarthritis (nr-axSpA) — this is a type of arthritis that affects the spine and sacroiliac joints, but without visible damage on X-rays.
- Your symptoms must still be active despite trying NSAIDs (like ibuprofen or naproxen).
- You must have signs of inflammation, such as an abnormal MRI or elevated C-reactive protein (CRP) in your blood.
- Your disease must be active, with a BASDAI score of at least 4 and a pain score of at least 4 on a 0-10 scale.
- You cannot have other active inflammatory conditions like inflammatory bowel disease (IBD) or uveitis, and you cannot have certain infections (like TB, HIV, or hepatitis B or C).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether secukinumab (a targeted medicine given by injection) can reduce symptoms and disease activity in adults with active ankylosing spondylitis. You may be considered if other common anti-inflammatory medicines have not worked well enough or you could not take them.
This study is testing how well a new medication called Xeligekimab works in real-life settings for people with moderate to severe plaque psoriasis. It may help if you are starting this treatment for the first time and want to contribute to learning more about its effects.
This study tests a new medication (called 608) to see if it helps reduce pain and inflammation in people with a type of spinal arthritis that isn't visible on X-rays. If you have persistent back pain and signs of inflammation, this treatment might offer a new option to feel better.
This trial tests a new oral medication that may reduce inflammation and improve symptoms in people with axial spondyloarthritis. It is in early phases, meaning the drug is still being studied for safety and effectiveness.
This trial tests a new medication called vilamakitug to see if it can reduce pain and inflammation in people with axial spondyloarthritis, a type of arthritis that affects the spine and joints. It may help those who haven't found relief with other treatments.
This study looks at how well different newer medications work for people with axial spondyloarthritis or psoriatic arthritis. It focuses on those just starting treatment with bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor.
Hear when a new Nr-axial Spondyloarthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.